To determine the impact of dose-dense chemotherapy administration on ovarian reserve in women undergoing treatment for breast cancer.
Patients and Methods:
We conducted a retrospective cohort study of reproductive age women who underwent dose-dense chemotherapy regimens with doxorubicin hydrochloride and cyclophosphamide with or without paclitaxel for a new diagnosis of breast cancer. We compared pre- and post-treatment serum antimullerian hormone (AMH) levels and assessed changes in AMH over time.
Results:
Fifty-seven patients met inclusion criteria. Median pre-treatment AMH was 2.9 ng/mL, whereas post-treatment AMH was 0.1 ng/mL, demonstrating a dramatic reduction in AMH levels after treatment with a dose-dense regimen. This change was independent of age and was sustained over 12 months from treatment completion.
Conclusions:
Dose-dense chemotherapy regimens for breast cancer lead to marked and sustained decreases in AMH irrespective of patient age.
de AlmeidaFK, RosaDD. Adjuvant dose-dense chemotherapy for breast cancer: Available evidence and recent updates. Breast Care (Basel), 2018; 13(6):447–452.
3.
EBCTG. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: A patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet, 2019; 393(10179):1440–1452.
4.
CitronML. Dose-dense chemotherapy: Principles, clinical results and future perspectives. Breast Care (Basel), 2008; 3(4):251–255.
5.
OktayK, HarveyBE, LorenAW. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update Summary. J Oncol Pract, 2018; 14(6):381–385.
6.
Committee. Fertility preservation and reproduction in patients facing gonadotoxic therapies: An Ethics Committee opinion. Fertil Steril, 2018; 110(3):380–386.
7.
di ClementeN, RacineC, PierreA, TaiebJ. Anti-Müllerian hormone in female reproduction. Endocr Rev, 2021; 42(6):753–782.
8.
BozzaC, PuglisiF, LambertiniM, et al.Anti-Mullerian hormone: Determination of ovarian reserve in early breast cancer patients. Endocr Relat Cancer, 2014; 21(1):R51–R65.
9.
LiX, LiuS, MaL, et al.Can anti-Müllerian hormone be a reliable biomarker for assessing ovarian function in women postchemotherapy?. Cancer Manag Res, 2020; 12:8171–8181.
10.
AndersonRA, WallaceWH. Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril, 2013; 99(6):1469–1475.
11.
American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: A committee opinion. Fertil Steril, 2020; 114(6):1151–1157.
12.
StreuliI, FraisseT, PilletC, et al.Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril, 2008; 90(2):395–400.
13.
WennersA, GrambachJ, KossJ, et al.Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial. BMC Cancer, 2017; 17(1):632.
14.
FornierMN, ModiS, PanageasKS, et al.Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer, 2005; 104(8):1575–1579.
15.
RibnikarD, RibeiroJM, PintoD, et al.Breast cancer under age 40: A different approach. Curr Treat Options Oncol, 2015; 16(4):16.
16.
AbusiefME, MissmerSA, GinsburgES, et al.The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer, 2010; 116(4):791–798.
17.
DezellusA, BarriereP, CamponeM, et al.Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer, 2017; 79:72–80.
18.
BinesJ, OleskeDM, CobleighMA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol, 1996; 14(5):1718–1729.
19.
RuddyKJ, GelberSI, TamimiRM, et al.Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol, 2014; 32(11):1151–1156.
20.
PartridgeA, PaganiO, NimanSM, et al.Abstract GS4-09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsive breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13). Cancer Res, 2023; 83(5_Suppl.):GS4-09-GS4-.
